Iclos Uruguay (originally known as Clausen) was founded in the early 20th century with a strong focus on the manufacture of chemicals. In 2007, the company’s current production plant was opened, becoming the first biological product plant in the country and the only one approved by the European Medicines Agency (EMA) in Uruguay. Now-a-days, Iclos Uruguay has a high-tech pharmaceutical plant in over 6,500 square meters, comprising two production plants following the most demanding international standards.
Gemabiotech is a member of AMEGA Biotech, the biopharmaceutical platform integrating development and production operations, designing all processes, from clone selection to purified protein production, and finished products formulation.
AMEGA has a team specialized in the development of biosimilars. The company has all necessary facilities, from molecular biology, cell culture and downstream process development, to a pre-clinical studies department, where more than 15 bacterial and mammalian processes are developed.
Research & Development
Iclos Uruguay has a Research and Development Department of segregated oral solid drugs. Developments in this area include immunosuppressants, oncological drugs (for the treatment of solid and hemo-oncological tumors), and enzyme inhibitors for autoimmune diseases such as rheumatoid arthritis.
Research & Development
The Research and Development Department of Iclos Uruguay has a Pharmaceutical Development sector and an Analytical Development sector for the development of new oncological and immunosuppressant drugs. This area allows for small-scale production, necessary for tests that make possible innovation in processes and products, and allowing to manufacture small test lots that help minimize the generation of toxic waste.
Research & Development
GEMABIOTECH Research and Development Unit began its activities in 1998, and has since carried out the development, production, purification, characterization, and analysis of a wide range of recombinant products. This area is responsible for the generation of the master cell bank and the working cell bank.